In the article by Rockstroh et al., appearing in the Journal of Acquired Immune Deficiency Syndromes, Vol. 62, No. 5, pp. 483-486, entitled “A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results,” the statement in the Results sections that reads “Of the 6 subjects with resistance to EVG/COBI/FTC/TDF, 5 occurred during the first 48 weeks and 1 occurred during the second 48 weeks of treatment, 2 which failed with M184V but no integrase resistance” is incorrect. The statement should read: “Of the 6 subjects with resistance to EVG/COBI/FTC/TDF, 5 occurred during the first 48 weeks as previously described2 and 1 occurred during the second 48 weeks of treatment developing both M184V in reverse transcriptase and E92Q in integrase.”
Rockstroh J, DeJesus E, Henry K, et al.. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483–486.